EUVIMEDEUVIMED entdecken
Crossref

Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug

Jih Ru Hwu, Avijit Panja, Shwu Chen Tsay, Wen-Chieh Huang, Tapan Kumar Pradhan, Chen-Sheng Yeh, Wu Chou Su, Li Xing Yang, Dar Bin Shieh

Journal of Biotechnology and Biomedicine · 2026 · 09 (03)

DOI: 10.26502/jbb.2642-91280222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biotechnology and Biomedicine, 2026. Verfasst von Jih Ru Hwu und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hwu, J. R., Panja, A., Tsay, S. C., Huang, W., Pradhan, T. K., Yeh, C., Su, W. C., Yang, L. X., & Shieh, D. B. (2026). Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug. Journal of Biotechnology and Biomedicine, 09(03). https://doi.org/10.26502/jbb.2642-91280222

Vancouver

Hwu JR, Panja A, Tsay SC, Huang W, Pradhan TK, Yeh C, et al. Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug. Journal of Biotechnology and Biomedicine. 2026;09(03). doi:10.26502/jbb.2642-91280222

BibTeX
@article{Hwu2026,
  author = {Hwu, Jih Ru and Panja, Avijit and Tsay, Shwu Chen and Huang, Wen-Chieh and Pradhan, Tapan Kumar and Yeh, Chen-Sheng and Su, Wu Chou and Yang, Li Xing and Shieh, Dar Bin},
  title = {Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug},
  journal = {Journal of Biotechnology and Biomedicine},
  year = {2026},
  volume = {09},
  number = {03},
  doi = {10.26502/jbb.2642-91280222}
}
Kostenlos starten →